Board of Directors

 
  • Chief Executive Officer and Director

    Mr. Raad was appointed Chief Executive Officer in 2019.  Prior to his appointment, he served as Pulmatrix’s Chief Business Officer and led commercial and business development efforts.  He has 20 years of commercial health care and life science leadership experience and most recently served as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider.  Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD.  During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the US and Japan.  Earlier in his career he also gained direct launch experience with Sporanox, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the Pulmatrix PUR1900 program.  Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management.

  • Managing Director, ARCH Venture Partners

    Dr. Gillis has been a director of Pulmatrix since October 2009. Since 2005, Dr. Gillis has been a Managing Director at ARCH Venture Fund, a venture capital firm. From 1994 to 2005, Dr. Gillis served as Chief Executive Officer and chairman of the board of directors of Corixa Corporation, which he co-founded in October 1994. Previously, Dr. Gillis served as a director, head of research and development, chief scientific officer and acting chief executive officer of Immunex Corporation, which he co-founded. As a former director and chairman of Trubion Pharmaceuticals, Inc., Dr. Gillis led its acquisition by Emergent BioSolutions in the fall of 2010. Dr. Gillis currently serves as a director of Shire plc, Accelerator Corporation, Homology Medicines, Inc. and serves as director and chairman of VentiRX Pharmaceuticals, Inc., Theraclone Sciences, Inc., Lycera Corp., Faraday Pharmaceuticals, Inc., Oncofactor Corp., VBI Vaccines and PhaseRx, Inc. Dr. Gillis received his B.A. in Biology and English from Williams College and his Ph.D. in Biological Science from Dartmouth College. Pulmatrix believes that Dr. Gillis’s experience in the venture capital industry, particularly with biotechnology and pharmaceutical companies, qualifies him to serve as a member of Pulmatrix’s board of directors.

  • Entrepreneur-in-residence at Polaris Partners

    Mr. Higgins was appointed to serve as a director of Pulmatrix in March 2015. Mr. Higgins is currently an Entrepreneur-in-residence at Polaris Partners and is a board member at Genocea Biosciences, Voyager Therapeutics, Kindex Pharmaceuticals, Madauder Therapeutics, Sea Pharmaceuticals and Private Equity Access Fund, II. Mr. Higgins served as senior vice president, chief operating officer and chief financial officer of Ironwood Pharmaceuticals Inc. and led its finance, operations and strategy efforts from 2003 to 2014 and through its initial public offering and the launch of its first commercial product. Prior to 2003, Mr. Higgins spent seven years and held a variety of senior business positions at Genzyme Corporation, including vice president of corporate finance and vice president of business development. Prior to joining Genzyme Corporation, Mr. Higgins led Procept, Inc. from founding through its initial public offering. Mr. Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College.

  • Executive Chairman, Kala Pharmaceuticals

    Mr. Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas including respiratory.  He was CEO of Civitas Pharmaceuticals, a biotechnology company with a novel pulmonary drug delivery platform, and also led the development and launch of several respiratory products as CEO of Sunovion Pharmaceuticals and during his tenure at Novartis. Mr. Iwicki is currently on the boards of directors of Kala Pharmaceuticals, Aimmune, Nimbus Therapeutics, Merus and Taris Biomedical.

  • Co-Founder and General Partner, Polaris Partners

    As a founding partner of Polaris Partners, Terry brings more than 25 years of successful early stage investing experience in medical and information technology companies.

    Prior to starting Polaris in 1996, Terry spent seven years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. Terry began his career in venture capital at Golder, Thoma and Cressey in Chicago.

    As a venture capitalist, Terry has invested in more than 50 companies. He also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkermes), and MicroCHIPS (private). Companies Terry has supported have touched more than 60 million patients and directly saved over 400,000 lives. These companies have raised over $6 billion in equity and corporate capital. As a group, they have achieved a combined peak enterprise value of over $50 billion.

    In 2015, Terry was listed as one of Scientific American’s Worldview 100, visionaries who continue to reshape biotechnology and the world. In 2014, Terry was chosen to receive the Irish America Healthcare & Life Sciences 50 Award. In 2013, Terry was listed as one of Forbes’ Top Life Sciences Investors, and he received The Boston Irish Business Award. In 2011, Terry was listed in Forbes’ Midas 100 List of Top Tech Investors. He is also a recipient of the Massachusetts Society for Medical Research Award, and the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Harvard and the City of Jerusalem. He was awarded honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science.

    Terry is emeritus chairman of the National Venture Capital Association (NVCA), which represents ninety percent of the venture capitalists in the United States. During his tenure as NVCA Chairman, Terry testified before Congress for Dodd-Frank Wall Street Reform and Consumer Protection Act. He is also chairman of the Global Venture Capital Congress.

    Terry chairs the board of the Thayer School of Engineering, Dartmouth College. He also sits on the boards of MIT’s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and The Healthcare Initiative Advisory Board (HBS).

    Terry holds an MBA from Harvard Business School, an MS in engineering from The Thayer School at Dartmouth College, and a BS in physics and economics from Hobart College.

  • Director, President and Chief Executive Officer, Arena Pharmaceuticals

    Amit D. Munshi was appointed to serve as a director of Pulmatrix in June 2017. He is currently the President and Chief Executive Officer of Arena Pharmaceuticals, Inc. Previously, Mr. Munshi served as President and Chief Executive Officer and a director of Epirus Biopharmaceuticals, Inc. from May 2012 to May 2016. Prior to Epirus, Mr. Munshi served as Chief Executive Officer of Percivia LLC, a biotechnology company, from 2011 to 2012, was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., from 2005 to 2010, and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker Graduate School of Management at Claremont Graduate University. Mr. Munshi has more than 25 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Mr. Munshi currently serves on the board of Cytrellis Biosystems, Inc.

  • Chief Medical Officer, Acceleron Pharma, Inc.

    Dr. Sherman, became a director of Pulmatrix in September 2016.  He has served as the Chief Medical Officer of Acceleron Pharma, Inc. since May 2006 and as the Executive Vice President Acceleron Pharma, Inc. since March 2015.  Prior to joining Acceleron, he served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg® by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an M.D. from Dartmouth Medical School. Dr. Sherman brings to the Board his medical background and extensive experience as a biopharmaceutical industry leader in clinical research and development.

  • * Chairman of the Board of Directors

    * Chairman of the Board of Directors


 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design